1. Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks. (March 2023) Authors: Buti, M.; Wedemeyer, H.; Aleman, S.; Chulanov, V.; Morozov, V.; Sagalova, O.; Stepanova, T.; Gish, R. G; Lloyd, A.; Kaushik, A. M; Suri, V.; Manuilov, D.; Osinusi, A. O; Flaherty, J.; Pandey, S.; Singh, B.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data. (March 2023) Authors: Asselah, T.; Lampertico, P.; Aleman, S.; Bourliere, M.; Streinu-Cercel, A.; Bogomolov, P.; Morozov, V.; Stepanova, T.; Lazar, S.; Suri, V.; Manuilov, D.; Mercier, R.C.; Tseng, S.; Ye, L.; Flaherty, J.F.; Osinusi, A.; Brunetto, M.; Wedemeyer, H. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis. (March 2023) Authors: Lampertico, P.; Aleman, S.; Blank, A.; Bogomolov, P.; Chulanov, V.; Mamonova, N.; Morozov, V.; Sagalova, O.; Stepanova, T.; Suri, V.; Manuilov, D.; Ye, L.; Flaherty, J.F.; Osinusi, A.; Cornberg, M.; Brunetto, M.; Wedemeyer, H. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗